

Summary of achievements 2014–2020



The European & Developing Countries Clinical Trials Partnership

Supported by the European Union

Investments in calls for proposals



Participation in EDCTP activities

60 countries participate in EDCTP-funded activities:

19 European countries and **41 African countries**

EDCTP investments in R&D

Clinical studies €634.59 M

to support **123 collaborative research projects** with large-scale clinical trials and other clinical research activities conducted by European-African consortia. Total funding €752.74 M for 395 projects awarded to date.



Clinical research capacity €75.99 M

to support **76 projects** that strengthen the enabling environment for conducting clinical trials and clinical research. \mathbf{A}

Fellowship programme €42.16 M

26.2

to support **196 fellowships projects** that focus on the career development of African-based scientists.

Medical interventions

Collaborative research projects by disease



• Tuberculosis, 31 grants €186.44 M

- Malaria, 13 grants
- HIV & HIV-associated infections, 19 grants €109.54 M
- Emerging diseases, 34 grants €81.31 M
- Neglected infectious diseases, 17 grants €62.04 M
- Diarrhoeal diseases, 5 grants €45.49M
- Lower respiratory tract infections, 4 grants €28.09 M

Collaborative research projects by intervention



• Drugs, 49 grants €279.58 M

- Vaccines, 24 grants €238.39 M
- Diagnostics, 39 grants €86.65 M
- Non-intervention specific topics, 4 grants €21 M
- Product-focused implementation research, 7 grants €8.97 M

274 is the total number of clinical studies awarded by EDCTP2 since 2014. Of these, 45% (124) are interventional (clinical trials) studies of drugs and vaccines and 55% (150) are non-interventional studies (observational studies of drugs and vaccines, diagnostics and prognostics, and other studies).

Clinical trials centres and sites involved in clinical studies

36 sub-Saharan African countries host recruitment sites of EDCTP-funded collaborative clinical studies.

63% (78) of clinical trials are phase II and




Comoros(2)

III studies of drugs and vaccines aiming to deliver key evidence on safety and efficacy. The phase III trials also aim to provide data to support product registration.


Clinical trials of drugs and vaccines by phase

17% (21) of the trials involve postlicense (phase IV) studies aiming to influence health policies and practice, and optimise the delivery of medical interventions for the wide range of sub-Saharan African health systems and diverse populations.



Population in clinical studies

8% (23) of all studies target pregnant women and their children. Other key populations are also involved in the studies, such as newborns and infants (47; 17%), children (72, 26%) and adolescents (72; 26%).





Sharing results

149 peer-reviewed publications resulted from EDCTP2 studies, so far.

88 (59%) had at least one leading author from a partner institution from sub-Saharan Africa.



Epidemic preparedness and response

3 calls for proposals launched in 2020, that address COVID-19:

- Mobilisation of funding for COVID-19 research in sub-Saharan Africa
- Capacity development for disease outbreak and epidemic response in sub-Saharan Africa, in collaboration with Africa CDC
- Addressing gender and diversity gaps in clinical research capacity at the EDCTP Regional Networks of Excellence

€11.75 M invested to support 24 projects in sub-Saharan Africa aiming to manage and/or prevent the spread of the current COVID-19 outbreak. COVID-19 research response is also carried out by the two consortia, PANDORA-ID-NET and ALERRT, funded by EDCTP through earlier investments of €20 M in epidemic preparedness research.


ALERRT consortium network

PANDORA-ID-NET consortium network

Collaboration and capacity development

EDCTP projects involve **244** sub-Saharan African organisations. These account for **59%** of total EDCTP funding.







€23 M has been invested in capacity strengthening of the sub-Saharan African research networks and establishment of an African cohort of epidemiologists and biostatisticians.

16 sub-Saharan African

countries are members of the EDCTP Association. In the EDCTP 2014-2020 work plans, these members have submitted 120 Participating States' Initiated Activities (PSIAs) of total committed value of ≤ 67 M.



Trainees on EDCTP grants by type



9956 participants benefitted from EDCTP project-related trainings and workshops on topics such as:

study protocol Good Clinical Practice specimen collection research and administration

epidemics preparedness

European coordination



14 European countries are member of the EDCTP Association. In the EDCTP 2014-2020 work plans, these members have submitted 280 Participating States' Initiated Activities (PSIAs) of total committed value of €995 M. PSIAs are research activities within the scope of the EDCTP programme that are funded and implemented by one or more member countries. 18 COVID-19 related PSIAs were submitted by the European member countries in 2020 with an indicative commitment of €180.63 M. Additionally, member countries mobilised cash funding for the emergency call for proposals on COVID-19 research response.

€171.37 M is the total cash received from the European member countries to the EDCTP programme.

European member countries cash contribution to the EDCTP programme

United Kingdom		€135.73 M
Sweden	€15.63 M	
Germany	€14.44 M	
France	€3.00 M	
Portugal	€1.00 M	
The Netherlands	€0.81 M	
Spain	€0.53 M	
Ireland	€0.02 M	
Norway	€0.01 M	

Partnerships




14% (253 out of 1723) of all participations in EDCTP-funded projects involve private-sector organisations. They include private not-for-profit entities (179 or 10%) such as foundations and product development partnerships, private-forprofit organisations (22 or 1%) such as pharmaceutical companies and smalland-medium enterprises (52 or 3%). Private sector organisations were awarded €127.63 M by EDCTP in 2020. **€26.92** M has been leveraged from partners for the launch of joint or coordinated calls for proposals.

Partner contributions to joint initiatives launched with EDCTP

€10 N	Coalition for Epidemic Preparedness Innovations (CEPI)
€5 M	WHO/TDR
€2.55 M	EFPIA members
€2 M	Fundación Mundo Sano-España
€1.67 M	Novartis International AG
€1.62 M	Fondation Botnar
€1.50 M	GlaxoSmithKline (GSK)
€1.22 M	African Research Excellence Fund (AREF)
€0.50 M	Switzerland
€0.47 M	Calouste Gulbenkian Foundation
€0.40 M	Leprosy Research Initiative (LRI)

€340.02 M has been leveraged as co-funding to EDCTP projects through the EDCTP strategic calls for proposals (€244.54 M in cash and €95.48 M in-kind).

Co-funding in EDCTP projects (top 5 funders)



The EDCTP2 programme is supported under Horizon 2020, the European Union's Framework Programme for Research and Innovation.





